Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated With Sorafenib

Cancer Research - United States
doi 10.1158/0008-5472.can-18-1089
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Mp78-10 the Influence of Genetic Variants on Clinical Outcomes and Toxic Effects in Patients With Advanced Renal Cell Carcinoma Treated With Sorafenib: A Multi-Center Research

Journal of Urology
Urology
2016English

Novel Hematological Biomarkers Predict Survival in Renal Cell Carcinoma Patients Treated With Nephrectomy

Archives of Medical Science
Medicine
2017English

Post-Progression Survival and Progression-Free Survival in Patients With Advanced Hepatocellular Carcinoma Treated by Sorafenib

Hepatology Research
HepatologyInfectious Diseases
2015English

Critical Appraisal of Sorafenib in the Treatment of Chinese Patients With Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2014English

Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
2015English

Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma

Urology
Urology
2008English

Long Duration of Stable Disease May Improve Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Acta Hepatologica Japonica
Hepatology
2012English

Gender-Related Differences in Surgically Treated Patients With Renal Cell Carcinoma

Journal of Urological Surgery
2018English

Attenuation of Liver Stiffness in Sorafenib-Treated Patients With Advanced Hepatocellular Carcinoma

Hepatoma Research
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy